港股異動|康諾亞升超9% 國家醫保局正調整創新藥的定價政策
康諾亞(2162.HK)升9.13%,報24.5港元。消息面上,國家醫療保障局醫藥價格和招標採購司副司長翁林佳在“第十五屆中國醫藥企業家科學家投資家大會”上透露,國家醫保局正在調整創新藥的定價政策,在《新冠治療藥品價格形成指引》基礎上,對創新藥上市早期階段的價格採取相對寬鬆的管理。此外,公司日前表示正就CM310治療成年人中重度特應性皮炎的新藥申請(NDA)與國家藥監局進行溝通,預期將於2023年提交新藥申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.